About: Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients
Creator	Libby, Peter Liu, Tianxiao Luo, Songyuan Shi, Guo-Ping
source	Elsevier; Medline; PMC
abstract	The widespread coronavirus SARS-CoV-2 has already infected over 4 million people worldwide, with a death toll over 280,000. Current treatment of COVID-19 patients relies mainly on antiviral drugs lopinavir/ritonavir, arbidol, and remdesivir, the anti-malarial drugs hydroxychloroquine and chloroquine, and traditional Chinese medicine. There are over 2118 on-going clinical trials underway, but to date none of these drugs have consistently proven effective. Cathepsin L (CatL) is an endosomal cysteine protease. It mediates the cleavage of the S1 subunit of the coronavirus surface spike glycoprotein. This cleavage is necessary for coronavirus entry into human host cells, virus and host cell endosome membrane fusion, and viral RNA release for next round of replication. Here we summarize data regarding seven CatL-selective inhibitors that block coronavirus entry into cultured host cells and provide a mechanism to block SARS-CoV-2 infection in humans. Given the rapid growth of the SARS-CoV-2-positive population worldwide, ready-to-use CatL inhibitors should be explored as a treatment option. We identify ten US FDA-approved drugs that have CatL inhibitory activity. We provide evidence that supports the combined use of serine protease and CatL inhibitors as a possibly safer and more effective therapy than other available therapeutics to block coronavirus host cell entry and intracellular replication, without compromising the immune system.
has issue date	2020-05-26(xsd:dateTime)
bibo:doi	10.1016/j.pharmthera.2020.107587
bibo:pmid	32470470
has license	no-cc
sha1sum (hex)	b50534c64cca221969fcaa7e3c2c2af403247e5f
schema:url	https://doi.org/10.1016/j.pharmthera.2020.107587
resource representing a document's title	Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients
has PubMed Central identifier	PMC7255230
has PubMed identifier	32470470
schema:publication	Pharmacol Ther
resource representing a document's body	covid:b50534c64cca221969fcaa7e3c2c2af403247e5f#body_text
is schema:about of	named entity 'coronavirus' named entity 'host' named entity 'hydroxychloroquine' named entity 'infected' named entity 'coronavirus' »more»

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software